Journal of Clinical and Translational Endocrinology最新文献

{"title":"Enrollment in a fracture liaison service does not guarantee post fracture follow-up","authors":"Craig R. Jenkins,&nbsp;Jessica D. Collier,&nbsp;Claire I. Yee,&nbsp;Blake T. Langlais,&nbsp;Jaxon K. Quillen,&nbsp;Patricia M. Verona,&nbsp;Michael D. Whitaker,&nbsp;Curtiss B. Cook","doi":"10.1016/j.jcte.2025.100409","DOIUrl":"10.1016/j.jcte.2025.100409","url":null,"abstract":"<div><h3>Objective</h3><div>To assess post fracture outpatient follow-up adherence in a cohort of patients enrolled in a fracture liaison service (FLS).</div></div><div><h3>Methods</h3><div>We analyzed FLS registry data for patients who were hospitalized with fragility fractures from June 2020 through December 2022 and determined the proportion of patients who kept their follow-up appointments in outpatient endocrinology and orthopedic clinics.</div></div><div><h3>Results</h3><div>We identified 295 patients who were eligible for the FLS pathway; from this group, 57 declined an endocrinology follow-up visit. Of the remaining 238 patients, 95 (40 %) had appointments but subsequently canceled and 7 (3 %) did not show up for their appointments. No follow-up information was documented for 77 patients (32 %). Thus, only 59 of 238 (25 %) kept their appointments in endocrinology. In the univariate analyses, age, severity of illness, and discharge status were associated with follow-up adherence only in the orthopedic cohort (<em>P</em> ≤ 0.02). However, the adjusted analyses did not identify any variables that were associated with follow-up adherence in either the endocrinology or orthopedic cohorts.</div></div><div><h3>Conclusion</h3><div>Post fracture outpatient follow-up was lower for the endocrinology cohort, as compared with the orthopedic cohort, even among patients enrolled in an FLS. Factors that were previously postulated to influence follow-up, including those described in this study, showed no association with appointment-keeping behavior. Possibly, the importance of osteoporosis treatment is not emphasized or the treatment options are unappealing to our patient population. Further study is needed to determine the specific obstacles contributing to the low endocrine post fracture follow-up rate.</div></div><div><h3>Key Message</h3><div>Fracture liaison services can reliably reduce future fracture events, but follow-up adherence after hospitalization remains challenging. We compared the rates of endocrinology vs orthopedic follow-up in a single cohort of patients hospitalized for fragility fractures and assessed variables that potentially contributed to the lower endocrinology follow-up rate (eg, travel distance, age, marital status). However, no factors were identified as having a significant effect. These data show that the specific obstacles previously thought to contribute to lower-than-expected post fracture follow-up rates are misleading, and novel approaches are needed to address this widespread issue.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100409"},"PeriodicalIF":4.2,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collagen in pituitary adenomas: A comprehensive review of biological roles and clinical implications","authors":"Jie Liu ,&nbsp;Yong Yao ,&nbsp;Lian Duan ,&nbsp;Lin Lu ,&nbsp;Huijuan Zhu ,&nbsp;Yongning Li ,&nbsp;Jun Gao","doi":"10.1016/j.jcte.2025.100408","DOIUrl":"10.1016/j.jcte.2025.100408","url":null,"abstract":"<div><div>Pituitary adenomas (PAs) are common brain tumors, accounting for about 15% of all brain neoplasms. Although generally benign, they can lead to serious complications through mass effects and hormone dysregulation. Emerging evidence suggests that collagen, a major component of the extracellular matrix (ECM), plays a pivotal role in PA pathophysiology. Collagen provides both structural integrity and biochemical cues within the tumor microenvironment (TME), influencing cellular behaviors and intercellular interactions. Recent studies indicate that collagen remodeling in PAs is dynamic, with alterations in collagen composition and organization affecting tumor growth, invasion, and hormone secretion. Collagen degradation products and collagenase activity may also facilitate tumor invasion into adjacent tissues. Additionally, collagen has been implicated in immune modulation, acting as a physical barrier that restricts immune cell infiltration and promotes immune evasion through receptor-mediated signaling. Metabolically, collagen may serve as an energy source or modulate metabolic pathways to sustain tumor proliferation. Clinically, collagen content in PAs correlates with tumor consistency, which has implications for surgical resection strategies. Moreover, serum collagen is emerging as a potential non-invasive biomarker for PA diagnosis and prognosis. Targeting collagen synthesis, degradation, or its mechanotransductive signaling pathways represents a promising therapeutic avenue.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100408"},"PeriodicalIF":4.2,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144614279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor","authors":"Espérie Burnet ,&nbsp;Deborah Grunewald ,&nbsp;Etienne Larger ,&nbsp;Florence Camus-Bablon ,&nbsp;Catherine Eisenhauer ,&nbsp;François Mifsud ,&nbsp;Clémence Martin ,&nbsp;Isabelle Honoré ,&nbsp;Reem Kanaan ,&nbsp;Nicolas Carlier ,&nbsp;Johanna Fesenbeckh ,&nbsp;Helen Mosnier-Pudar ,&nbsp;Pierre-Régis Burgel","doi":"10.1016/j.jcte.2025.100407","DOIUrl":"10.1016/j.jcte.2025.100407","url":null,"abstract":"<div><h3>Background</h3><div>Elexacaftor-tezacaftor-ivacaftor (ETI) became available for adults with cystic fibrosis (CF) in 2019, but its impact on CF-related diabetes (CFRD) remains unclear.</div></div><div><h3>Methods</h3><div>A single-center retrospective cohort study was conducted among adults with CFRD to examine the change in insulin dose-adjusted Hemoglobin A1c (IDAA1c). Linear mixed effects model (LMEM) analysis was used to investigate the change in IDAA1c between baseline and 24 months of follow up, comparing an ETI-treated group to an unexposed group. Baseline values were those documented at treatment initiation for the ETI-treated group and in March 2020 (±3 months) for the unexposed group.</div></div><div><h3>Results</h3><div>A total of 49 adults were included, 39 were treated with ETI and 10 were not. Median [Interquartile range] time since CFRD diagnosis at baseline was 13 [7–18] and 14 [10–18] years, respectively (p = 0.610). In the ETI-treated group, mean weight increased by a 4.44 kg (95 % Confidence Interval, 95 %CI: 3.08 to 5.79, p &lt; 0.001), insulin total daily dose decreased by 5 units (95 %CI: −9 to 0, p = 0.033), and hemoglobin A1c (%) decreased by 0.65 points (95 %CI: −0.96 to −0.34, p &lt; 0.001). No change was observed in the unexposed group. LMEM analysis found a numerically significant association between ETI and decreased IDAA1c, estimated at −1.14 points (95 %CI: −2.35 to 0.06, p = 0.067) after adjusting for age, sex, time since CFRD diagnosis and the introduction of Metformin.</div></div><div><h3>Conclusion</h3><div>A numerically significant association between ETI and IDAA1c decrease was observed in adults with established CFRD after 24 months of treatment, suggesting ETI contributed to improved glycemic control.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100407"},"PeriodicalIF":4.2,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144571328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma","authors":"Jiahong Chen ,&nbsp;Peisheng Huang ,&nbsp;Yongcheng Shi ,&nbsp;Shanshan Mo ,&nbsp;Cheng-Ya Hsu ,&nbsp;Shumin Fang ,&nbsp;Chuanfan Zhong ,&nbsp;Le Zhang ,&nbsp;Lanting Zuo ,&nbsp;Jianming Lu ,&nbsp;Weide Zhong ,&nbsp;Zhuoya Huang ,&nbsp;Zhong Dong","doi":"10.1016/j.jcte.2025.100406","DOIUrl":"10.1016/j.jcte.2025.100406","url":null,"abstract":"<div><h3>Background</h3><div>Adrenocortical carcinoma (ACC) is an uncommon and highly aggressive tumor with a grim prognosis. Numerous investigations have elucidated a close association between the dysregulated expression of multiple genes within tumors and the initiation as well as progression of neoplasms. These dysregulated genes not only exert pivotal roles in tumorigenesis but also harbor significant potential as prognostic biomarkers.</div></div><div><h3>Methods</h3><div>This study utilized transcriptomic data from public databases of ACC and normal tissue samples to screen for differentially expressed genes (DEGs). Subsequently, univariate Cox regression and receiver operating characteristic (ROC) curve were employed to identify potential prognostic biomarkers for ACC. Immunohistochemistry and in vitro cell experiments were conducted to validate the expression and potential functions of Cell division cycle 20 (CDC20) in ACC cells. Additionally, we analyzed the relationship between CDC20 and CD8+ T cells, immunotherapy response, somatic mutations, and copy number variations.</div></div><div><h3>Results</h3><div>CDC20 has emerged as an independent adverse prognostic factor in ACC, with significantly elevated expression levels. In vitro cell experiments have demonstrated that downregulation of CDC20 expression suppresses proliferation and migration of ACC cells. Notably, our study has identified CDC20 expression as most closely associated with TP53 mutation. Additionally, CDC20 expression levels exhibit a negative correlation with infiltration of CD8+ T cells. Patients with low CDC20 expression may show improved response to anti-PD-1 immunotherapy.</div></div><div><h3>Conclusion</h3><div>CDC20 serves as a reliable and robust biomarker in ACC, playing a crucial role in predicting survival outcomes and assessing immunotherapy response in adult and childhood ACC patients.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100406"},"PeriodicalIF":4.2,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated glucose levels in melanoma patients − a real-world analysis","authors":"Joan Walter ,&nbsp;Bojan Bojanic ,&nbsp;Manuel Dittli ,&nbsp;Nadia Fehr ,&nbsp;Thomas Sartoretti ,&nbsp;Moritz Schwyzer ,&nbsp;Katharina Binz ,&nbsp;Antonio G. Gennari ,&nbsp;Matthias Ernst ,&nbsp;Martin W. Huellner ,&nbsp;Michael Messerli","doi":"10.1016/j.jcte.2025.100405","DOIUrl":"10.1016/j.jcte.2025.100405","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the glycemic status of consecutive melanoma patients undergoing standardized capillary fasting blood glucose (cFBG) assessment prior to fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) examination.</div></div><div><h3>Methods</h3><div>This retrospective study included 336 consecutive melanoma patients at the University Hospital Zurich, Switzerland. Fasting cFBG levels were measured prior to FDG PET/CT and classified according to American Diabetes Association guidelines. Multivariable linear regression analysis was performed to identify independent predictors of cFBG levels. Sensitivity analyses were performed on patients examined before 11 AM and fasting for 8 h as well as patients without known diabetes.</div></div><div><h3>Results</h3><div>The cohort included 336 melanoma patients with a median age of 67 years (IQR 57–76), 36 % female (122/336), and 12 % (40/336) with known diabetes mellitus. The median cFBG was 103 mg/dL (IQR 94–112; 5.7 mmol/L, IQR 5.2–6.2). Overall, 58 % (194/336) of patients had non-normal cFBG levels (≥100 mg/dL; ≥5.6 mmol/L), consistent with findings from a sensitivity analysis of patients presenting before 11 AM, where 58 % (115/198) exhibited non-normal levels. Excluding patients with known diabetes, 56 % (165/296) of patients had non-normal cFBG levels, with 7 % (20/210) having levels ≥126 mg/dL (≥7.0 mmol/L), indicative of possible undiagnosed diabetes mellitus. Multivariable linear regression analysis identified male gender, active disease, and subcutaneous fat as independent predictors of cFBG levels, whereas traditional risk factors such as BMI, visceral fat, hypertension or lack of exercise were not independent predictors.</div></div><div><h3>Conclusion</h3><div>More than half of melanoma patients have elevated cFBG levels, even in those without known diabetes, highlighting the need for improved glycemic screening and management.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100405"},"PeriodicalIF":4.2,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 inhibitor therapy in overweight and obese patients with cystic fibrosis-related diabetes: Case series","authors":"Ammar Ahmed ,&nbsp;Roshini Asirvatham ,&nbsp;Jagdeesh Ullal ,&nbsp;Amir Moheet","doi":"10.1016/j.jcte.2025.100403","DOIUrl":"10.1016/j.jcte.2025.100403","url":null,"abstract":"<div><div>Cystic fibrosis-related diabetes (CFRD) is the most prevalent extrapulmonary comorbidity in CF. While insulin remains the standard treatment, increasing rates of overweight and obesity due to CFTR modulators highlight the need for new therapies. SGLT2 inhibitors, effective in type 2 diabetes, have not been studied in CFRD. This case series presents eight CFRD patients treated with SGLT2 inhibitors alongside insulin for one year. Half had BMI reductions (1.33–2.89 kg/m2); others had increases. Glycemic control improved in six, worsened in two due to insulin nonadherence. Insulin adjustments showed no pattern. One patient discontinued due to genital infections; overall tolerance was high.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100403"},"PeriodicalIF":4.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting accelerated fetal growth in pregnancy: beyond maternal hyperglycemia – The role of prothymosin-α, inflammatory cytokines, and angiogenic factors","authors":"Maria Mirabelli ,&nbsp;Marta Greco ,&nbsp;Stefano Iuliano ,&nbsp;Francesco Dragone ,&nbsp;Eusebio Chiefari ,&nbsp;Daniela Foti ,&nbsp;Antonio Brunetti","doi":"10.1016/j.jcte.2025.100404","DOIUrl":"10.1016/j.jcte.2025.100404","url":null,"abstract":"<div><div><em>Aim</em>: This study investigates prothymosin-α (ProT-α), an immunomodulatory protein, as a potential biomarker for insulin resistance in gestational diabetes (GDM), and as a predictor of fetal growth by 20 weeks of gestation (wg). <em>Methods</em>: Forty-six women with singleton pregnancies were classified into GDM (n = 8) and normal glucose tolerance (NGT; n = 38) groups based on 75 g OGTT results. Maternal glucose, insulin, cytokines, and ProT-α levels were measured, and fetal growth was assessed by ultrasound at 20 wg, focusing on abdominal circumference (AC) and estimated fetal weight (EFW) percentiles. <em>Results</em>: Women with GDM were older, had a higher BMI, glucose, and insulin levels, with fetuses showing higher AC and EFW percentiles. IL-8, TNFα, and IL-1α were lower in the GDM group, while ProT-α was also lower but not significantly. ProT-α inversely correlated with EFW percentiles, independent of GDM. Regression analysis identified 2-hour post-load glucose, VEGF, and EGF as positive predictors of fetal growth acceleration, while IL-10 and ProT-α were negative predictors. <em>Conclusions</em>: Fetal growth is influenced by maternal glucose, inflammation, and angiogenesis. ProT-α may serve as an independent biomarker for predicting fetal growth in early pregnancy, suggesting further investigation into its role in GDM, obesity, and insulin resistance.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100404"},"PeriodicalIF":4.2,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “False negative rate and concordance of ThyGeNEXT®+ThyraMIR® testing with post-thyroidectomy histopathology” [J. Clin. Translat. Endocrinol. 40 (2025) 100396]","authors":"Sobrina S. Mohammed ,&nbsp;Daniel Mettman ,&nbsp;Mariana Garcia-Touza ,&nbsp;Betty Drees ,&nbsp;Maricel Ridella","doi":"10.1016/j.jcte.2025.100397","DOIUrl":"10.1016/j.jcte.2025.100397","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100397"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Prediction of BRAF and TERT status in PTCs by machine learning-based ultrasound radiomics methods: A multicenter study” [J. Clin. Translat. Endocrinol. 40 (2025) 100390]","authors":"Hui Shi ,&nbsp;Ke Ding ,&nbsp;Xue Ting Yang ,&nbsp;Ting Fan Wu ,&nbsp;Jia Yi Zheng ,&nbsp;Li Fan Wang ,&nbsp;Bo Yang Zhou ,&nbsp;Li Ping Sun ,&nbsp;Yi Feng Zhang ,&nbsp;Chong Ke Zhao ,&nbsp;Hui Xiong Xu","doi":"10.1016/j.jcte.2025.100394","DOIUrl":"10.1016/j.jcte.2025.100394","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100394"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucocorticoids: The culprit behind metabolic disorders in primary Aldosteronism? A narrative review","authors":"Piotr Kmieć ,&nbsp;Renata Świątkowska-Stodulska","doi":"10.1016/j.jcte.2025.100401","DOIUrl":"10.1016/j.jcte.2025.100401","url":null,"abstract":"<div><div>In recent years, a new approach toward aldosterone secretion autonomy has emerged as a consequence of studies demonstrating its continuum from subclinical, mild to overt and severe forms. These clinical insights were accompanied by immense progress in deciphering the tissue and cellular pathology underlying primary aldosteronism (PA).</div><div>Thus far, research has not sufficiently elucidated the relationships between overt PA and metabolic disorders. Similarly, the role of glucocorticoid cosecretion in this patient group remains unclear. Milder than overt PA forms have been scarcely investigated.</div><div>This review critically analyzes these issues on the basis of a literature search of the PubMed database.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100401"},"PeriodicalIF":4.2,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}